PSEUDO-12
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jun 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PSEUDO-12 is an oral extended-release suspension approved in 1987 by UCB Pharma. The mechanism of action and indication are unknown, limiting assessment of therapeutic positioning. As a legacy small-molecule product, it likely serves a chronic condition with established clinical utility.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting brand team focused on generic transition and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PSEUDO-12 offers minimal career growth; the approaching LOE and zero linked job openings indicate a wind-down product with limited hiring. Career value lies in generic transition, regulatory compliance, and operational efficiency—suitable for mid-level professionals managing decline rather than building brand momentum.
Brand ManagerSenior Commercial Manager
Worked on PSEUDO-12 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.